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Abstract: The incidence of papillary thyroid carcinoma (PTC) has been increasing worldwide. PTC is
the most common type of differentiated thyroid cancer and usually shows good prognosis. However,
some PTC is driven to advanced stage by epithelial-mesenchymal transition (EMT)-mediated drug
resistance, which is particularly noticeable in pediatric patients. There are limited options for systemic
treatment, necessitating development of new clinical approaches. Here, we aimed to clarify genetic
differences due to age of patients with PTC, and thereby aid in developing novel therapeutics. Patients
with biochemically and histologically confirmed PTC were included in this study. PTC cells were
acquired from young and older patients showing drug resistance, and were compared via microarray
analysis. Cellular proliferation and other properties were determined after treatments with lenvatinib
and sorafenib. In vivo, tumor volume and other properties were examined using a mouse xenograft
model. Lenvatinib-treated group showed obvious suppression of markers of anti-apoptosis, EMT, and
the FGFR signaling pathway, compared with control and Sorafenib-treated group. In the xenograft
models, lenvatinib treatment induced significant tumor shrinkage and blocked the proto-oncogene
Bcl-2 (B cell lymphoma/leukemia gene-2) and FGFR signaling pathway, along with reduced levels
of EMT markers, compared with control and Sorafenib-treated group. Our findings clarify the
age-dependent characteristics of pediatric PTC, giving insights into the relationship between young
age and poor prognosis. Furthermore, it provides a basis for developing novel therapeutics tailored
to the age at diagnosis.
Keywords: papillary thyroid carcinoma; EMT; FGFR; Lenvatinib; Sorafenib
1. Introduction
Thyroid carcinoma is the most common malignancy in adolescent and young adult women,
and incidence is increasing across all age groups [1–3]. Thyroid carcinoma in children presents with
several distinct clinical features when compared with that in adults. Despite a more advanced disease
at presentation and a higher risk of recurrence, the prognosis of childhood differentiated thyroid
carcinoma (DTC) is generally fairly good [4,5]. Biological and molecular mechanisms explaining the
differing clinical behavior of pediatric and adult DTC have thus far been elusive. Several studies have
suggested that the spectrum of mutations may differ between tumors of pediatric patients and those
of adults [6–8]. Although there have been several previous studies describing molecular differences
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to explain the aggressive behavior of DTC in pediatric patients, no study has yet provided a clear
explanation of the mechanism of action. As these aggressive pediatric cancers frequently acquire
drug resistance, there is a need for effective clinical guidelines [9,10]. Recent studies have shown
that the development of epithelial–mesenchymal transition (EMT) in advanced cancer cells not only
results in metastasis, but also acts as a crucial contributing factor in fibroblast growth factor receptor
(FGFR) signaling-mediated drug resistance [11,12]. Although the connection between EMT and drug
resistance was confirmed a while ago, the mechanism remains unclear for advanced cancer. EMT is
a physiological process wherein epithelial cells show collapse of cell-cell junctions and permanently
transition to a state with the property of migratory cells [13]. Although EMT accounts for an essential
aspect of resistance to ErbB-targeting compounds, a lack of understanding regarding the molecular
mechanisms fundamental to this process has inhibited the progress of clinical approaches aimed
at this drug-resistant state [14,15]. Some studies have shown that EMT and the FGFR signaling
pathway play crucial roles in EMT-mediated poor prognosis and stemness of pediatric cancer [16–19].
These previous studies propose that stemness and aggressiveness of the pediatric cancer is related to
EMT, which results in drug resistance, and consequently poor prognosis. Diverse mechanisms and
molecules have been associated with poor clinical outcomes for advanced thyroid cancer [20,21]. In the
current study, we focused on the relationship between drug resistance and EMT in pediatric thyroid
cancer to explain the poor clinical outcomes [22]. Specifically, we investigated the potential underlying
drug resistance mechanism, to aid the development of novel clinical approaches to address the issues
related to drug resistance.
2. Results
2.1. Patients
The patients included 11 males and 41 females (Table 1), with a mean age at initial operation
of 12.5 ± 2.9 years (range 5–15 years). A familial history of thyroid cancer was seen in 4 patients.
The mean follow-up period was 9.8 ± 5.5 years. Cervical lymph node metastases were observed in
nearly 80% of our cases. At initial presentation, two patients had distant lung metastasis. Recurrence
was found in 9 (17.3%) of the 52 patients. TNM stage was defined using the AJCC Cancer Staging
Manual, 8th Edition [23].
Table 1. Clinical and pathological characteristics of thyroid carcinoma in 52 patients aged 15 years old
and less at diagnosis. SD, standard deviation.
Variables Patients
N = 52
Age (years), mean ± SD (range) 12.5 ± 2.9 (5–15)
Male:female ratio, n (%) 11 (21.2):41 (78.8)
Initial presentation, n (%)
Incidentaloma 18 (34.6%)
Palpable mass 33 (63.5%)
Thyrotoxicosis 1 (1.9%)
Famliy history of thyroid cancer, n (%) 4 (7.7%)
Histology, n (%)
Papillary 45 (86.5%)
Follicular 6 (11.5%)
Medullary 1 (1.9%)
Tumor size (cm), mean ± SD 2.4 ± 1.4
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Table 1. Cont.
Variables Patients
N = 52
Extrathyroidal extension 32 (61.5%)
Vascular invasion 41 (78.8%)
TNM stage
T stage
T1:T2:T3:T4 13 (25.0):4 (7.7):31 (59.6):4(7.7)
N stage
N0:N1a:N1b 12 (23.1):9 (17.3):31 (59.6)
M stage
M0:M1 50 (96.2):2 (3.8)
Time to recurrence (years), mean ± SD (range) 8.3 ± 5.6 (1.1–11.7)
Follow up period (years), mean ± SD (range) 9.8 ± 5.5 (4.1–13.7)
2.2. EMT Marker and FGFR Signaling Pathway Are Higher in Pediatric than in Adult Patients
To clarify the distinction between PTC of the young and older patients, we acquired four tissues
(patients were treated at the Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.)
derived from 4 different patients with PTC (two young patients aged 4 and 13 and two old patients
aged 47 and 52) (Table 2, Information for PTC from Severance Hospital; we decided to refer to the
PTC in young age—under 15—as ‘GSPY’, and that in old age—over 40—as ‘GSPO’). Given that gene
expression is largely dependent on age, we considered that GSPY achieves an aggressive phenotype by
transcriptional reprogramming compared with that in GSPO.
Table 2. Characteristics of patient-derived papillary thyroid cancer cell line, including viability after
drug treatment of all thyroid cancer cell lines examined.
Variables GSPY1 GSPY2 GSPO1 GSPO2
Age at Diagnosis 4 13 52 47
Gender Female Female Female Female
Primary Disease
Site Thyroid Thyroid Thyroid Thyroid
Stage T4aN1bM0 T4aN1bM0 T4aN1bM1 T3N1bM1
Primary Pathology
(subtype)
Papillary thyroid
cancer
(conventional)
Papillary thyroid
cancer
(conventional)
Papillary thyroid
cancer
(conventional)
Papillary thyroid
cancer
(conventional)
Classification of
specimen used for
culture
Fresh tumor Fresh tumor Fresh tumor Fresh tumor
Obtained from
Gangnam
Severance Hospital,
Seoul, Korea
Gangnam
Severance Hospital,
Seoul, Korea
Gangnam
Severance Hospital,
Seoul, Korea
Gangnam
Severance Hospital,
Seoul, Korea
To test this, we performed a gene expression microarray analysis to compare the GSPY and GSPO
patient-derived PTC cells (Figure 1A). Many genes were significantly differentially expressed between
GSPY and GSPO cells, suggesting that multiple biological processes were reprogrammed depending
on age mediated cancer cell differentiation. Genes related to FGFR and EMT were particularly induced
in GSPY (Figure 1A). Consistent with this, the protein expression related to FGFR and EMT was more
dominant in GSPY than in GSPO (Figure 1B).
Cancers 2020, 12, 448 4 of 15
Cancers 2020, 12, x FOR PEER REVIEW 4 of 16 
 
 
 
 
Figure 1. Gene expression profiles of patient-derived papillary thyroid cancer (PTC) cells. Gene expression 
analysis using a microarray approach between PTC of young (GSPY) and old (GSPO) individuals. (A) Gene 
expression profiles based on microarray. Hierarchical clustering analysis for comparison of GSPY and 
GSPO samples. (B) Immunoblot analysis for markers of FGFR signaling pathway and EMT in GSPY and 
GSPO samples. 
These data prove that genes and proteins related to the FGFR signaling pathway and EMT are 
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proliferation in GSPY1 vs. GSPO1 and GSPY2 vs. GSPO2 in the presence and absence of these 
compounds using an MTT assay (Figure 2A–D, Table 3). The results indicated that both sorafenib 
and lenvatinib reduced the proliferation of GSPY and GSPO cells, compared with that of vehicle 
control-treated cells. However, sorafenib weakly suppressed the cell proliferation of GSPY compared 
with that of GSPO, with the difference being significant (Figure 2). Collectively, these results imply 
that lenvatinib is a more potent agent against GSPY. 
Table 3. IC50 based on cell proliferation assay. Each data point represents the mean of 3 independent MTT 
assays; IC50 was determined in triplicate. SD, standard deviation. 
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GSPY2 Thyroid cancer; Papillary Human 20.25 (±0.1) 16.54 (±0.3) 
GSPO1 Thyroid cancer; Papillary Human 9.84 (±0.5) 10.23 (±0.4) 
GSPO2 Thyroid cancer; Papillary Human 10.12 (±0.2) 10.98 (±0.1) 
 
Figure 1. Gene expression profiles of patient-derived papillary thyroid cancer (PTC) cells.
Gene expression analysis using a microarray approach between PTC of young (GSPY) and old
(GSPO) individuals. (A) Gene expression profiles based on microarray. Hierarchical clustering analysis
for comparison of GSPY and GSPO samples. (B) Immunoblot analysis for markers of FGFR signaling
pathway and EMT in GSPY and GSPO samples.
These data prove that genes and proteins related to the FGFR signaling pathway and EMT are
expressed more highly in GSPY than in GSPO. Consequently, we focused on the mechanism by which
aggressiveness was acquired via the FGFR signaling path ay and E T.
2.3. Lenvatinib More Effectively Inhibited the Proliferation of SPY than Sorafenib
To investigate the anti-cancer activit es and IC5 rafenib and lenvat nib, we ssayed cell
proliferation in GSPY1 vs. GSPO1 and GSPY2 SPO2 in the pr sence and absence of these
comp unds using an MTT assay (Figure 2A–D, Tabl ). e results indicated that both sorafenib
and lenvatinib reduced the proliferation of GSPY and SP cells, compared with that of vehicle
control-treated cells. However, sorafenib weakly suppressed the cell proliferation of GSPY compared
with that of GSPO, with the difference being significant (Figure 2). Collectively, these results imply
that lenvatinib is a more potent agent against GSPY.
Table 3. IC50 based on cell proliferation assay. Each data point represents the mean of 3 independent
MTT assays; IC50 was determined in triplicate. SD, standard deviation.
Cell Line Hisopathology Animal Cell Proliferation IC50 (µM)
Sorafenib Lenvatinib
GSPY1 Thyroid cancer; Papillary u an 17.24 (±0.5) 15.75 (±0.2)
GSPY2 Thyroid cancer; Papillary u a 20.25 (±0.1) 16.54 (±0.3)
GSPO1 Thyroid cancer; Papillary u an 9.84 (±0.5) 10.23 (±0.4)
GSPO2 Thyroid cancer; Papillary Human 10.12 (±0.2) 10.98 (±0.1)
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Figure 2. Anti-cancer effects of lenvatinib or sorafenib on patient-derived papillary thyroid cancer 
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lenvatinib or sorafenib alone: (A,C) GSPY; (B,D) GSPO. The data points were calculated as mean % 
of the value observed in the solvent-treated control. All experiments were repeated at least 3 times. 
Data are represented as means ± SD. * p < 0.05, ** p < 0.01, and *** p < 0.005 compared with control. 
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lenvatinib is a multikinase inhibitor that inhibits FGFR signaling pathway, which effectively means 
the inhibition of EMT-mediated FGFR signaling pathway in GSPY. Together, these data indicate that 
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2.4. Lenvatinib Induces More Effective Reduction of EMT-Mediated FGFR Signaling Pathway in
Patient-Derived Thyroid Cancer Cells
Protein expression related to FGFR signaling pathway and EMT was more dominant in GSPY than
in GSPO, this difference might account for the differences towards the anticancer drugs. Immunoblot
analyses of protein levels in GSPY and GSPO cell lines indicated that lenvatinib showed marked
decreases in the levels of PKC, MEK, p-ERK, Snail, and Zeb-1, which are well-known markers of
FGFR signaling pathway and EMT, compared with that in response to sorafenib (Figure 3A). Notably,
the anti-apoptotic marker Bcl-2 was highly suppressed in the lenvatinib treatment group compared
with that in the sorafenib group. The TUNEL assay confirmed that lenvatinib induced apoptosis in
GSPY and GSPO cell lines more potently than sorafenib (Figure 3B,C). Unlike sorafenib, lenvatinib is a
multikinase inhibitor that inhibits FGFR signaling pathway, which effectively means the inhibition
of EMT-mediated FGFR signaling pathway in GSPY. Together, these data indicate that lenvatinib
effectively suppresses GSPO as well as GSPY.
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Immunoblot analysis for markers of FGFR signaling pathway (PKC, MEK and p-ERK1/2), EMT (Snail 
and Zeb1), and anti-apoptotic factor (Bcl-2) in young (GSPY) and older (GSPO) patient-derived 
papillary thyroid cancer cells. (B,C) TUNEL assay of GSPY and GSPO; TUNEL-positive (apoptotic) 
cells are indicated (×400): (B) GSPY1 vs. GSPO1; (C) GSPY2 vs. GSPO2. 
Figure 3. The expression of markers associated with the FGFR signaling pathway, EMT,
and anti-apoptosis were significantly suppressed by lenvatinib compared with that by sorafenib.
(A) Immunoblot analysis for markers of FGFR signaling pathway (PKC, MEK and p-ERK1/2), EMT
(Snail and Zeb1), and anti-apoptotic factor (Bcl-2) in young (GSPY) and older (GSPO) patient-derived
papillary thyroid cancer cells. (B,C) T EL assay of SPY and SP ; T EL-positive (apoptotic)
cells are indicated ( 400): ( ) SP 1 vs. SP 1; ( ) SPY2 vs. SP 2.
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2.5. Significant Tumor Shrinkage was Induced by Lenvatinib in a Xenograft Model of The Patient-Derived
PTC Cells
To investigate the anti-cancer effects of sorafenib and lenvatinib in vivo, we developed a mouse
xenograft tumor model with patient-derived PTC cells (GSPY1 vs. GSPO1, GSPY2 vs. GSPO2).
Sorafenib used alone did not markedly suppress GSPY1 and 2 compared with GSPO1 and 2 cell
xenograft tumors; however, lenvatinib resulted in tumor suppression in both GSPY- and GSPO-grafted
mice (Figure 4A–D). Moreover, there was no evidence of systemic toxicity or treatment-related death
in any group. Mouse body weight was not significantly influenced by treatment with sorafenib or
lenvatinib (Figure 4E–H). The sorafenib and lenvatinib treatment groups had smaller tumor volumes
than those in untreated mice. Interestingly, lenvatinib showed more significant tumor shrinkage than
sorafenib on GSPY, unlike on GSPO (Figure 4I–L).
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Figure 4. Tumor-sel ctive anti-cancer effects of lenvatinib or sorafenib in patient-derived papillary
thyroid cancer cell xenografts in vi o. Athymic nude mice with established tumors were treated with
the indicated inhibitors. Data represent the mean tumor volumes. Inhibit on of tumor progression by
therapy with lenvatinib or sorafenib in mice grafted with patient-derived papillary thyroid cancer cell:
(A,E,I) GSPY1; (B,F,J) GSPO1; (C,G,K) GSPY2; (D,H,L) GSPO2 (n = 10 mice/group). (A–D) Change in
tumor volume. (E–H) The compounds had no signific nt effect on mouse body weight. (I–L) W t of
the dissected tumors. * p < 0.05, ** p < 0.01, and *** p < 0.005 com ared with the control.
The lenvatinib treatment group also showed reduced levels of PKC, MEK, p-ERK, Snail, and Zeb-1
in GSPY and GSPO groups, compared with that after sorafenib treatment (Figure 5A). Notably,
the lenvatinib treatment group also showed the stronger decrease in Bcl-2 expression compared with
that after sorafenib treatment (Figure 5A,B). Together, these results imply that lenvatinib may be
considered to have potent anti-cancer effects in GSPO as well as GSPY xenograft model.
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and GSPO samples. * p < 0.05, ** p < 0.01, and *** p < 0.005 compared with the control. 
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Figure 5. (A) Immunoblot analysis of FGFR signaling pathway, EMT, and anti-apoptotic-related
proteins in tumor tissues derived from xenograft models using young (GSPY) and older (GSPO)
patient-derived papillary thyroid cancer cells. (B) Immunohistochemical analysis of Bcl-2 protein
levels in paraffin-embedded xenograft tumor tissues. Scale bar, 80 µm. Lenvatinib and so afenib were
administered orally (p.o.), once every 2 days and total lysates or paraffin-embedded were prepared
from GSPY and GSPO xenograft model. The assay estimated the marker levels of FGFR signaling
pathway (PKC, MEK and p-ERK1/2), EMT (Snail and Zeb1), and anti-apoptotic factor (Bcl-2) in GSPY
and GSPO samples. * p < 0.05, ** p < 0.01, and *** p < 0.005 compared with the control.
3. Discussion
The clinical features of DTC are markedly different based on age, and this fact is probably
associ ted with the differences in molecular profiles [24,25]. The high number of patients in whom no
known genetic event was identified suggests that other genetic/epigenetic factors may be associated
with the pathogenesis and biological behavior of pediatric DTC [26,27]. Cervical lymph node metastasis
at diagnosis was observed in nearly 80% of our cases, while they were detected in 35% of adults in other
studies [28–30]. The mechanism of action for aggressiveness in pediatric thyroid cancer has not been
elucidated so far. Theref re, the current study attempted to reveal the reason for its aggressiveness in
young age, unlike thy oid c ncer in adults with r spect t the EMT-mediated FGFR sig aling pathway.
A gene expression microarray analysis was performed to compare young (GSPY) and old (GSPO)
patient-derived papillary thyroid cancer cells. Various genes were significantly differentially expressed
between GSPY and GSPO cases, indicating that EMT processes were reprogrammed depending on
cancer cell aggressiveness and stemness. Genes related to EMT were significantly induced in GSPY
than in GSPO There has been much controversy over the appropriate treat ent for adult patients and
pediatric cases. Recognition a d discovery of age-associated diagnostic markers, especially i pediatric
patients with cancer would be significant in deciding a reasonable therapeutic approach. We were
particularly interested in examining cancer cells isolated from pediatric patients who showed drug
resistance [31]. A well-known study suggested that therapeutic failure in malignancies of pediatric
cancer is due to drug resistance [32,33]. In cancer, EMT is associated with malignant progression,
invasion, metastasis, and drug resistance [34–37]. CSCs (cancer stem cells) were found in poorly
differentiated cancer or anaplastic thyroid cancer and have stem cell-like peculiarities [38–41] such as the
ability for self-renewal, and were connected with metastasis, recurrence, and therapeutic resistance [42].
Recently, CSCs were associated with many cancers, including pediatric cancer [43]. Furthermore,
a connection between EMT, drug resistance, and CSCs was recently confirmed [44]. Particularly,
CSCs and cells showing EMT were considered to be crucial for drug resistance and metastasis,
as observed in many human malignant or recurrent cancers [44]. Several studies have also indicated
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the relationship between EMT and drug resistance in CSCs [15,44,45]. Interestingly, pediatric cancers
have properties similar to CSCs with respect to EMT-mediated stemness.
In the current study, in vivo experiments using a mouse xenograft tumor model indicated that
sorafenib alone could not markedly suppress GSPY compared GSPO cases; however, lenvatinib
treatment resulted in tumor suppression in both GSPY and GSPO cases. Our findings indicate that the
drug resistance in pediatric PTC, i.e., sorafenib-resistant patient-derived PTC cell, could be inhibited
by lenvatinib, through the inhibition of the EMT-mediated FGFR signaling pathway and Bcl-2. It is
a well-known fact that the anti-apoptotic factor and proto-oncogene Bcl-2 is a key player in the
control of apoptosis [46–48]. These results resolutely showed that Bcl-2 is also involved in EMT,
an essential mechanism in the drug resistance of pediatric PTC [49,50]. These findings can be useful
to design future rational clinical studies on pediatric patient with drug resistant cancer cell in order
to develop effective therapies. In microarray experiments, however, it is thought that there will be
more signaling pathways involved in these outcomes. Further studies are needed to assess current
outcomes. Furthermore, more research will be needed next study due to the limitation of only four
patient outcomes in this study.
It is noteworthy that these findings suggest that the therapeutic trials based on genetics, such as
those involving the inhibition of the EMT-mediated FGFR signaling pathway, are a potentially effective
new clinical approach for the care of pediatric patients with CSCs having drug-resistant properties.
4. Materials and Methods
4.1. Patients
The patients recruited for this study underwent thyroid operation, including thyroidectomy and
cervical lymph node dissection, and were≤15 years of age at the time of surgery. They were treated from
March 2003 to December 2015 at the Gangnam Severance Hospital (Seoul, South Korea). The details
of the patients’ presentations, family history, surgical and pathological findings, and outcome were
obtained from the database of Thyroid Cancer Center.
4.2. Patient Tissue Specimens
Fresh tumors were acquired from patients with biochemically and histologically established PTC
who were treated at the Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Fresh tumors were obtained during surgical resection of thyroid cancer primary and metastatic sites.
Some patients with thyroid cancer were chosen depending on cancer subtype. The research protocol
was approved by the Institutional Review Board of the Thyroid Cancer Center, Gangnam Severance
Hospital, Yonsei University College of Medicine (IRB Protocol: 3-2019-0281, Cell samples were acquired
from patients at the Severance Hospital, Yonsei University College of Medicine, Seoul, Korea).
4.3. Tumor Cell Isolation and Primary Culture
After resection, tumors were kept in normal saline with antifungal and antibiotics and moved
to the laboratory. Normal tissue and fat were removed, and the tissues were rinsed with 1× Hank’s
Balanced Salt Solution. Tumors were minced in a tube with dissociation medium containing Dulbecco’s
Modified Eagle’s Medium/Nutrient Mixture F-12 (DMEM/F12) with 20% fetal bovine serum (FBS)
supplemented with 1 mg/mL collagenase type IV (Sigma, St. Louis, MO, USA; C5138). The minced and
suspended tumor cells were filtered through sterile nylon cell strainers with 70-micron pores (BD Falcon,
Franklin Lakes, NJ, USA), rinsed with 50 mL of 1× Hank’s Balanced Salt Solution, and centrifuged at
220× g for 5 min. Cells were re-suspended in RPMI-1640 (Hyclone, South Logan, UT, USA) medium
with 10% FBS (Hyclone) and 2% penicillin/streptomycin solution (Gibco, Grand Island, NY, USA).
Cell viability was determined using the trypan blue dye exclusion method.
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4.4. Cell Culture
The patient-derived PTC cells were isolated and grown in RPMI-1640 medium with 10% FBS
(cells were authenticated by short tandem repeat profiling, karyotyping, and isoenzyme analysis).
4.5. Cell Proliferation Assay
Cell proliferation was measured using the MTT assay. Cells were seeded in 96-well plates at
6 × 103 cells per well and incubated overnight to achieve 80% confluency. Cells were incubated for the
indicated times prior to the determination of cell proliferation using the MTT reagent (Roche, Basel,
Switzerland; 11465007001) according to the manufacturer’s protocol. Absorbance was measured at
550 nm. Viable cells were counted by trypan blue exclusion. Data were calculated as a percentage of the
signal observed in vehicle-treated cells and are shown as the means ± SEM of triplicate experiments.
4.6. Microarray Experiment and Data Analysis
RNA purity and integrity were evaluated using an ND-1000 Spectrophotometer (NanoDrop,
Wilmington, DE, USA) and an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
RNA labeling and hybridization were performed using the Agilent One-Color Microarray-Based Gene
Expression Analysis protocol (Agilent Technology, V 6.5, 2010). Briefly, 100 ng of total RNA from
each sample was linearly amplified and labeled with Cy3-dCTP. The labeled cRNAs were purified
using an RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). The concentration and specific activity
of the labeled cRNAs (pmol Cy3/µg cRNA) were measured using the NanoDrop ND-1000. Then,
600 ng of each labeled cRNA was fragmented by adding 5 µL of 10× blocking agent and 1 µL of 25×
fragmentation buffer, and then heated at 60 ◦C for 30 min. Finally, 25 µL of 2× GE hybridization
buffer was added to dilute the labeled cRNA. Hybridization solution (40 µL) was dispensed into the
gasket slide and assembled to the Agilent SurePrint G3 Human GE 8X60K, V3 Microarrays (Agilent®).
Raw data were extracted using Agilent Feature Extraction Software (v11.0.1.1). The raw data for each
gene were then summarized automatically in an Agilent feature extraction protocol to generate the
raw data text file, providing expression data for each gene probed on the array. Gene-enrichment
and functional annotation analysis for the significant probe list was performed using gene ontology
(www.geneontology.org/) and Kyoto Encyclopedia for Genes and Genomes (http://kegg.jp) analyses.
All data analysis and visualization of the differentially expressed genes were conducted using R 3.1.2
(www.r-project.org).
4.7. Evaluation of Apoptotic Cell Death
Cells were fixed with 4% paraformaldehyde solution for 48 h and then analyzed using a terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) kit (Promega, Madison, WI, USA).
The apoptotic cells (fluorescent green) and total cells were counted by fluorescence microscopy. Images
were acquired under a confocal microscope (LSM Meta 700, Carl Zeiss, Oberkochen, Germany) and
analyzed using the Zeiss LSM Image Browser software, version 4.2.0121.
4.8. Immunoblot Analysis
Cells were washed twice with cold phosphate-buffered saline and lysed on ice with protein
extraction buffer (Pro-Prep, iNtRON Biotechnology, Seoul, Korea) following the manufacturer’s protocol.
Protein concentrations were determined by a BCA assay (Pierce Biotechnology, Rockford, IL, USA).
Equal amounts of protein (20 µg) were separated on 8–10% sodium dodecyl sulfate-polyacrylamide
gels; the resolved proteins were electro-transferred onto polyvinylidene fluoride membranes (Millipore,
Bedford, MA, USA). The membranes were subsequently blocked with 5% nonfat milk in TBST for 1 h
at room temperature and incubated with appropriate concentrations of primary antibodies against
PKC, MEK, Snail, Zeb1,2 (all from Abcam, Cambridge, UK) and p-ERK1/2, ERK1/2, Bcl-2, β-actin (all
from Santa Cruz Biotechnology, Dallas, TX, USA) overnight at 4 ◦C. The membranes were then rinsed
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3–5 times with TBST and probed with the corresponding secondary antibodies conjugated to horse
radish peroxidase (Santa Cruz) at room temperature for 1 h. After rinsing, the blots were developed
with ECL reagents (Pierce) and exposed using Kodak X-OMAT AR Film (Eastman Kodak, Rochester,
NY, USA) for 3–5 min. Uncropped images of the immunoblot analysis indicated on Supplementary
Figure S1).
4.9. Immunohistochemistry
All tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin wax following
standard protocols. Tissue sections (5 µm) were dewaxed, and antigen retrieval was performed in
citrate buffer (pH 6), using an electric pressure cooker set at 120 ◦C for 5 min. Sections were incubated
for 5 min in 3% hydrogen peroxide to quench endogenous tissue peroxidase. Primary monoclonal
antibodies against Bcl-2 (Abcam) was diluted with PBS at a ratio of 1:100 and incubated overnight at
4 ◦C. All tissue sections were counterstained with hematoxylin, dehydrated, and mounted.
4.10. Image Analysis
MetaMorph 4.6 software (Universal Imaging Co., Downington, PA, USA) was used for
computerized quantification of immunostained target proteins.
4.11. Human Papillary Thyroid Cancer Cell Xenografts
The patient-derived PTC cells (4.0 × 106 cells/mouse) were cultured in vitro and then injected
subcutaneously into the upper left flank region of 5- to 6-week-old female BALB/c nude mice.
After 13 days, tumor-bearing mice were assigned to groups randomly (n = 10/group) and administered
10 mg/kg lenvatinib (p.o.) and 40 mg/kg sorafenib (p.o.), once every 2 days. Tumor size was measured
every other day using calipers. Tumor volume was estimated using the following formula: L × S2/2
(L, longest diameter; S, shortest diameter). Animals were maintained under specific pathogen-free
conditions. All experiments were approved by the Animal Experiment Committee of Yonsei University.
4.12. Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla,
CA, USA). Immunohistochemistry results were evaluated by ANOVA followed by Bonferroni
post hoc tests. Values are expressed as the means ± standard deviation (SD). p < 0.05 indicated
statistical significance.
5. Conclusions
In conclusion, our study proposed that Bcl-2 is also involved in EMT, an essential mechanism
in the drug resistance of pediatric PTC. Consequentially, these findings can be useful to design
future rational clinical studies on pediatric patient with drug resistant cancer cell in order to develop
effective therapies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/2/448/s1,
Figure S1: Uncropped images of the immunoblot analysis. The image is indicated total protein lysate of the
patient-derived papillary thyroid cancer, Figures 1B, 3A and 5A.
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PTC Papillary Thyroid Carcinoma
EMT Epithelial-Mesenchymal Transition
FGFR Fibroblast Growth Factor Receptor
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IRB Institutional Review Board
DMEM/F12 Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture F-12
FBS Fetal Bovine Serum
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
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